Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants
Issued Date
2022-05-01
Resource Type
ISSN
03065251
eISSN
13652125
Scopus ID
2-s2.0-85121365116
Pubmed ID
34783372
Journal Title
British Journal of Clinical Pharmacology
Volume
88
Issue
5
Start Page
2203
End Page
2212
Rights Holder(s)
SCOPUS
Bibliographic Citation
British Journal of Clinical Pharmacology Vol.88 No.5 (2022) , 2203-2212
Suggested Citation
Wattanaruengchai P., Nathisuwan S., Karaketklang K., Wongcharoen W., Phrommintikul A., Lip G.Y.H. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants. British Journal of Clinical Pharmacology Vol.88 No.5 (2022) , 2203-2212. 2212. doi:10.1111/bcp.15145 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85942
Title
Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants
Other Contributor(s)
Abstract
Aims: This study aimed to evaluate the performance of HAS-BLED and ORBIT scores in predicting bleeding risk among Asian patients with nonvalvular atrial fibrillation (NVAF) using direct-acting oral anticoagulants (DOACs). Methods: A retrospective chart review was conducted among adult patients receiving DOACs for ≥6 months during January 2013 to December 2017 in 10 tertiary care hospitals in Thailand. The area under the receiver operating curve (AUROC) method or C-statistic was used to test the diagnostic accuracy for bleeding risk classification of HAS-BLED and ORBIT scores. The predictive performances of the two scores were compared using DeLong's method. Results: A total of 961 NVAF patients, 52.5% warfarin-naïve and 47.5% warfarin-experienced, with mean age of 74.25 ± 10.08 years, were included in the analysis. Mean HAS-BLED and ORBIT scores of the cohort were 1.98 ± 1.10 and 2.37 ± 1.71, respectively. During the mean follow-up time of 1.55 ± 1.13 years, 34 patients experienced major bleeding (2.28 events/100 patient-year). For the overall cohort, both the HAS-BLED and ORBIT scores showed similarly moderate predictive performance on bleeding with C-statistic (95% confidence interval) of 0.65 (0.57-0.74) and 0.64 (0.56-0.71), respectively. There was no statistical significance between the two scores (P =.62). Analysis based on the status of previous warfarin use was consistent with the overall cohort. Based on the calibration analysis, both HAS-BLED and ORBIT scores possessed moderate ability to identify those who experienced major bleeding from those who did not. Conclusion: Both HAS-BLED and ORBIT bleeding risk scores had moderate predictive performance in Asian NVAF patients receiving DOACs.